慢性淋巴细胞白血病的双重打击——BTK与BCL2抑制剂在当前及未来临床实践中的联合应用
Double Strike in Chronic Lymphocytic Leukemia-The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice.
作者信息
Zygmunciak Przemyslaw, Dancewicz Hanna, Stróżna Katarzyna, Błażowska Olga, Bieliński Krzysztof, Robak Tadeusz, Puła Bartosz
机构信息
Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland.
Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
出版信息
Int J Mol Sci. 2025 Mar 29;26(7):3193. doi: 10.3390/ijms26073193.
In the recent 2024 ESMO guidelines, the combination of venetoclax and ibrutinib was listed as one of the first-line treatment options for CLL patients. These drugs were first-in-class medicines that revolutionized CLL management, extending patients' overall survival even in cases refractory to immunochemotherapy. However, since the approval of both compounds, more and more Bruton Tyrosine Kinase inhibitors (BTKis) and B-cell lymphoma 2 inhibitors (BCL2is) have been discovered. Their efficacy and safety are the reasons for their use in monotherapy among both treatment-naïve and relapsed patients with CLL. Currently, several ongoing clinical trials are investigating the rationale for the combination of BCL2is and BTKis. In this review, we discuss the recent advancements in the field of co-therapy with BTKis and BCL2is.
在最近的2024年欧洲肿瘤内科学会（ESMO）指南中，维奈克拉和伊布替尼的联合用药被列为慢性淋巴细胞白血病（CLL）患者的一线治疗选择之一。这些药物是同类首创的药物，彻底改变了CLL的治疗方式，即使在对免疫化疗难治的病例中也能延长患者的总生存期。然而，自这两种化合物获批以来，越来越多的布鲁顿酪氨酸激酶抑制剂（BTKis）和B细胞淋巴瘤2抑制剂（BCL2is）被发现。它们的疗效和安全性是其在初治和复发的CLL患者中用于单药治疗的原因。目前，几项正在进行的临床试验正在研究BCL2is和BTKis联合用药的原理。在这篇综述中，我们讨论了BTKis和BCL2is联合治疗领域的最新进展。
Zotero 插件